New offerings expand GMP capabilities for cell and gene therapy

Lonza has added new solutions to its TheraPEAK® portfolio, introducing AmpliCell® Cytokines and 293-GT® Medium to support scalable, high-performance workflows for cell and gene therapy. These offerings are designed to streamline processes from research through GMP production, helping scientists and manufacturers accelerate development timelines.

TheraPEAK® AmpliCell® Cytokines provide consistent, biologically active molecules that enhance immune cell expansion, activation, and differentiation. Produced in mammalian systems, they maintain native-like structure and function, ensuring reproducibility across batches - an essential factor in sensitive research and clinical applications.

TheraPEAK® 293-GT® Medium is a chemically defined, animal-free system optimised for AAV production in suspension HEK293 cells. Compatible with standard transfection reagents and AAV enhancers, it supports high viral titres and favourable capsid ratios, offering a scalable, drop-in solution for gene therapy programs.

These additions build on TheraPEAK®’s proven track record, already used in FDA-approved therapies and more than 130 clinical trials worldwide, delivering regulatory-ready solutions for both discovery and production stages.

More information online